Captisol-enabled budesonide/azelastine nasal spray: Phase II data

In a double-blind, 3-way crossover Phase II trial in 108 patients, CDX-313 significantly improved nasal and eye symptoms vs. placebo during a 10-hour challenge (p<0.0001 for both). CDX-313 also had a ...